Your browser is no longer supported. Please, upgrade your browser.
TMDX TransMedics Group, Inc. daily Stock Chart
TransMedics Group, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own1.20% Shs Outstand21.85M Perf Week2.31%
Market Cap608.74M Forward P/E- EPS next Y-1.12 Insider Trans- Shs Float15.16M Perf Month-7.56%
Income-25.70M PEG- EPS next Q-0.98 Inst Own33.30% Short Float2.71% Perf Quarter-
Sales15.20M P/S40.05 EPS this Y-14.10% Inst Trans- Short Ratio1.14 Perf Half Y-
Book/sh-39.30 P/B- EPS next Y33.30% ROA- Target Price36.33 Perf Year-
Cash/sh0.56 P/C49.90 EPS next 5Y- ROE- 52W Range19.76 - 31.54 Perf YTD24.60%
Dividend- P/FCF- EPS past 5Y- ROI12.80% 52W High-11.67% Beta-
Dividend %- Quick Ratio1.20 Sales past 5Y- Gross Margin48.70% 52W Low40.99% ATR1.91
Employees92 Current Ratio1.90 Sales Q/Q88.00% Oper. Margin- RSI (14)- Volatility6.46% 7.56%
OptionableNo Debt/Eq- EPS Q/Q-40.70% Profit Margin- Rel Volume0.14 Prev Close28.00
ShortableYes LT Debt/Eq- EarningsJun 11 AMC Payout- Avg Volume359.58K Price27.86
Recom2.00 SMA203.32% SMA502.31% SMA2002.31% Volume51,446 Change-0.50%
May-28-19Initiated Morgan Stanley Equal-Weight
May-28-19Initiated JP Morgan Overweight
May-28-19Initiated Cowen Outperform
May-28-19Initiated Canaccord Genuity Buy
Jun-11-19 04:05PM  TransMedics Reports First Quarter 2019 Financial Results GlobeNewswire
02:30PM  TransMedics Group, Inc. to Host Earnings Call ACCESSWIRE
Jun-03-19 08:00AM  TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage GlobeNewswire
May-30-19 04:05PM  TransMedics to Report First Quarter 2019 Financial Results on June 11, 2019 GlobeNewswire
May-06-19 04:15PM  TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +10.52%
May-01-19 01:25PM  TransMedics Group IPO: What You Need To Know Benzinga
Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. The company offers its products in the United States and internationally. Transmedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.